XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.73 -0.84%

-$0.02 today

Market cap
$52.74M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.06M

Average 0.03M

XBIT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

XBiotech Inc.NASDAQ: XBIT

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $332K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $332K. Over 3 fiscal years it compounded at +37.3% a year.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $332K or moves back toward the trailing-twelve-month quarterly average of $83K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$332K— QoQ
Last fiscal yearDec 2025
$1.69M— YoY
LTMMar 2026
$332K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+37.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.69M USD
Year-over-year change
—
4-year CAGR
-26.6%

Cost of Revenue vs competitors

How XBIT compares with its peers on the latest reported figures

  • XBIT's LTM Mar 2026 cost of revenue of $332K is the 6th highest of the 9 companies compared; the peer median is $559.23K.
  • Over three fiscal years its annual growth of +37.3% compares with a peer median of -4.3%.
XBIT Competitors Peer median
Cost of Revenue for XBIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$23.48M +4.7%-12.1%35.5%
ACETAdicet Bio, Inc.LTM Mar 2026$1.34M ———
NTRBNutriband Inc.LTM Apr 2026$1.29M -19.4%+3.4%71.6%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$693K ——7.6%
ADAGAdagene Inc.LTM Jun 2024$425.46K ——52.2%
XBITXBiotech Inc.LTM Mar 2026$332K —+37.3%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$228K -137.1%——
Peer median (excluding XBIT) $559.23K-19.4%-4.3%43.8%

Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.39M4.01M000
Cost of Revenue5.82M651K001.69M
Gross Profit12.57M3.36M00(1.69M)
Gross Margin68.4%83.8%———
Research & Development28.27M31.54M32.85M37.76M47.39M
Selling, General & Admin9.39M6.31M4.66M4.71M8.3M
Operating Expenses37.66M37.85M37.51M42.47M54M
Depreciation & Amortization2.65M2.61M1.74M1.75M1.69M
EBITDA(22.81M)(30.97M)(22.57M)(36.01M)(43.53M)
EBITDA Margin-124.0%-772.4%———
Operating Income(25.08M)(34.49M)(37.51M)(42.47M)(55.69M)
Operating Margin-136.4%-860.1%———
Interest Income467K3.82M10.42M9.81M5.68M
Interest Expense000807K88K
Other Income / Expenses(376K)902K13.2M3.91M10.38M
Income Before Tax(25.46M)(33.59M)(24.31M)(38.56M)(45.31M)
Pre-Tax Margin-138.4%-837.6%———
Income Tax Expense(8.04M)(688K)244K(32K)235K
Net Income(17.41M)(32.9M)(24.56M)(38.53M)(45.54M)
Net Margin-94.7%-820.4%———
EPS (Basic)(0.58)(1.08)(0.81)(1.26)(1.49)
EPS (Diluted)(0.58)(1.08)(0.81)(1.26)(1.49)
Weighted Avg Shares30.04M30.44M30.32M30.46M30.49M
Weighted Avg Shares (Diluted)30.04M30.44M30.44M30.46M30.49M

XBiotech Inc.

NASDAQ:XBIT

Intrinsic Alpha fair value

Locked

Current Price

$1.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.